MIRO

Miromatrix Medical Inc. Common Stock

MIRO

Market cap $93M

Delisted

MIRO was delisted on the 12th of December, 2023.

Back to rankings

About: Miromatrix Medical Inc is a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives. Its pipeline products include; MiroliverELAP is External Liver Assist Product and is designed to provide liver dialysis for acute liver failure patients, Mirokidney is fully implantable bioengineered kidney intended to treat patients with end-stage renal disease, Miroliver is fully implantable bioengineered liver intended to treat patients with acute and chronic liver failure, Miroheart, Mirolung, and Miropancreas.

Employees: 76

Healthcare Drug Manufacturers - General

Financial journalist opinion

United Therapeutics and Miromatrix Medical Announce Completion of Tender Offer and Merger

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. & EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) and Miromatrix Medical Inc. (Nasdaq: MIRO) announced today that United Therapeutics, through its wholly owned subsidiary Morpheus Subsidiary Inc. (“Merger Sub”), has successfully completed the previously announced tender offer to acquire all outstanding shares of Miromatrix for a purchase price of $3.25 per share in cash at closing and an additional $1.75 per.

United Therapeutics and Miromatrix Medical Announce Completion of Tender Offer and Merger

United Therapeutics and Miromatrix Medical Announce Successful Tender Offer

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. & EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) and Miromatrix Medical Inc. (Nasdaq: MIRO) announced today the results of the previously announced tender offer by Morpheus Subsidiary Inc. (“Merger Sub”), a wholly owned subsidiary of United Therapeutics, to acquire all outstanding shares of Miromatrix for a purchase price of $3.25 per share in cash at closing and an additional $1.75 per share in cash upon th.

United Therapeutics and Miromatrix Medical Announce Successful Tender Offer

MIROMATRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Miromatrix Medical Inc. - MIRO

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Miromatrix Medical Inc. (NasdaqCM: MIRO) to United Therapeutics Corporation (NasdaqGS: UTHR). Under the terms of the proposed transaction, shareholders of Miromatrix will receive $3.25 in cash for each share of Miromatrix that they own, as well as an additional $1.75 per share in cash upon the achievement of a.

MIROMATRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Miromatrix Medical Inc. - MIRO

See News Rankings

Charts implemented using Lightweight Charts™